Nuvation Bio Inc. - NUVB

SEC Filings Our NUVB Tweets

About Gravity Analytica

Recent News

07.20.2026 - Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison
05.31.2026 - Patient-Reported Outcomes and Health-Related Quality of Life With Taletrectinib in Advanced ROS1+ NSCLC From the TRUST-II Study
05.31.2026 - Randomized, Double-Blind, Phase 3 TRUST-IV Study of Adjuvant Taletrectinib vs Placebo in Patients With Stage IB–IIIA ROS1+ Non-Small Cell Lung Cancer (NSCLC)
04.21.2026 - Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study
04.21.2026 - Taletrectinib in TKI-Naïve Patients With ROS1+ NSCLC: Updated Data From TRUST-I and TRUST-II
02.21.2026 - Efficacy and Safety of Taletrectinib in Patients With ROS1+ NSCLC: Updated Safety Analysis From the Phase 2 TRUST-I and TRUST-II Studies
12.08.2025 - Subgroup Analysis of Japanese Patients in the Phase II Study of Taletrectinib in Patients with ROS1+ NSCLC: The Global TRUST-II Study
12.03.2025 - Phase 2, multicenter, randomized clinical study to evaluate the efficacy and safety of safusidenib in patients with high-grade isocitrate dehydrogenase 1 (IDH1)-mutant glioma
11.18.2025 - Phase II Study of Safusidenib Erbumine in Patients with Chemotherapy- and Radiotherapy-Naïve Isocitrate Dehydrogenase 1-Mutated WHO Grade 2 Gliomas
10.18.2025 - TRUST-II Global Study: Efficacy and Safety of Taletrectinib After Prior Entrectinib Exposure in Patients With Advanced ROS1+ Non-Small Cell Lung Cancer

Nuvation Bio Inc. - NUVB

About Gravity Analytica

Recent News

Recent Filings